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Abstract
Aims: To determine the prevalence and associated risk factors of  diabetic peripheral neuropathy (DPN) among newly diag-
nosed diabetes mellitus patients in Mulago Hospital.
Methods: A cross-sectional study was conducted among 248 newly diagnosed adult diabetic patients. Using the standard Neu-
ropathy Symptom Score (NSS) and Neuropathy Disability Score (NDS) criteria, we screened them for neuropathy.  Data on the 
socio-demographics, age, duration of  symptoms and history of  diabetic ulcer were analyzed using a multiple logistic regression. 
A p-value <0.05 was considered significant.
Results: The majority of  study patients (62.1%) were male.  The overall prevalence of  DPN was 29.4 %.  Nearly sixteen percent 
had moderate neuropathy and only five percent had severe neuropathy.  Age above 60 years was significantly associated with the 
presence of  DPN; (OR 3.72; 95% CI 1.25 – 11.03; p=0.018). The history of  ever having a foot ulcer was significantly associated 
with peripheral neuropathy (OR 2.59; 95% CI: 1.03 – 6.49, p = 0.042).
Conclusion: DPN occurs in 1 in 4 of  newly diagnosed diabetic patients in Mulago hospital. Two thirds of  these patients had 
moderate to severe neuropathy. DPN was independently associated with increasing age. Early diagnosis of  diabetes mellitus, 
increased diabetes knowledge and regular blood sugar screenings would play an important role in identifying this problem.
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Introduction
The International Diabetes Federation (IDF) estimates 
that 19.8 million people have diabetes in Africa where 
approximately 75% are still undiagnosed1.  With the in-
cidence of  diabetes on the rise, the incidence of  diabetic 
complications like peripheral neuropathy is also expected 
to increase correspondingly2.  Approximately 50 percent 
of  patients with diabetes are estimated to develop neu-
ropathy depending on disease duration and diabetic con-
trol3.  Diabetic peripheral neuropathy is the commonest 
complication of  diabetes mellitus, and a major cause of  
limb amputations4.
The primary symptom of  diabetic peripheral neuropathy 
(DPN) is abnormal or loss of  sensation in the toes, which 
extends to involve the feet and leg in a stocking distribu-
tion5,6.  DPN predisposes to substantial morbidity, which 
includes not only susceptibility to foot or ankle fractures 
and ulceration leading to lower-limb amputations, but 
also neuropsychiatric co-morbidity such as depression7,8. 
These situations can negatively impact the quality of  life 
of  affected individuals. In general, however, the magni-
tude of  diabetic neuropathy in sub-Saharan Africans with 
diabetes has been less reliably quantified. There is paucity 
of  data on prevalence of  peripheral neuropathy and fac-
tors associated with peripheral neuropathy among newly 
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diagnosed diabetic patients in Uganda.  In this study, we 
determined the prevalence and factors associated with 
peripheral neuropathy among newly diagnosed diabetic 
patients attending Mulago teaching hospital.
Methods
Setting and study design
This was a cross sectional study carried out in the Mulago 
National Referral Teaching Hospital diabetic clinics and 
wards. The diagnosis of  diabetes was based on i). a gly-
cated hemoglobin A1C level ≥6.5%,  ii). A fasting plasma 
glucose (FPG) ≥126 mg/dL (7.0 mmol/L). Fasting was 
defined as no caloric intake for at least 8 h and iii). a prior 
clinical diagnosis (e.g., a patient in a hyperglycemic crisis 
or with classic symptoms of  hyperglycemia and a random 
plasma glucose ≥200 mg/dL)9. We classified smokers as 
having a history of  smoking and no history of  smoking, 
while alcohol was categorized as current alcohol con-
sumption and no alcohol consumption.
Sample size estimation
Sample size for prevalence was based on a study done by 
Dr. Pario Aldo in 2011(Masters’ thesis unpublished data) 
which gave the highest sample size. Required sample size 
is estimated using Keish and Leslie formula (1965) for 
estimating prevalence is 288 using the prevalence of  75%
N= Z2 P (1-P) / δ2. Where, N = the sample size, Z = 
the standard normal deviate at 95% confidence (1.96), 
P= Estimated prevalence is 0.75, δ2 = precision (0.05). 
Therefore 288 newly diagnosed diabetics were enrolled 
into this study.
Subject enrollment
Eligible subjects, who provided written informed con-
sent and met the inclusion criteria, were consecutively 
enrolled into this study from 1st December 2014 to 31st 
March 2015. 
The inclusion criteria of  study included; subjects aged 18 
years and above, newly diagnosed with diabetes with no 
prior history or medication of  diabetes mellitus.  We ex-
cluded subjects with chronic lower back pain, neurologi-
cal history and clinical exam suggestive of  myelopathies 
or radiculopathies, subjects with a Glasgow Coma Scale 
of  < 15 or who were aphasic and unable to cooperate 
with neurological examination.
Ethical considerations
Study approval was obtained from School of  Medicine 
Research and Ethics committee (SOMREC), Makerere 
University College of  Health Sciences Ref  Number 2014 
-148 and Uganda National Council of  Science and Tech-
nology.  Written informed consent was sought from all 
study participants and patient confidentiality was ensured. 
Study procedures
A pretested study questionnaire was administered to col-
lect demographic information as well as medical history 
of  diabetes and related diseases.  Study subjects were con-
secutively enrolled until the desired sample size was at-
tained.  A complete physical examination was performed 
including height in meters, weight in kilograms and blood 
pressure in mmHg.  Blood pressure was taken with man-
ual Sphygmomanometer with appropriate cuff  sizes for 
the patient arms. High blood pressure was defined as sys-
tolic blood pressure ≥ l40 mmHg or diastolic pressure ≥ 
90 mmHg10. Body Mass Index was calculated as weight 
divided by height squared (kg/m2).
Peripheral neuropathy screening and assessment
Neuropathy Disability Score (NDS): NDS consisted of  
four clinical tests on both feet.  The procedure was ex-
plained and the tests applied on the patient's hand prior 
to the examination.  The patient closed the eyes during 
the examination.  Each test was assessed with points to 
calculate the total disability score.  The clinical tests were 
carried as follows:  Pressure sensation was assessed us-
ing 10g (5.07) monofilament at 4 of  the 10 standard sites 
of  the sole of  the feet (plantar base of  the big toe, 2nd 
and 5th toes and at the heel), avoiding areas with callos-
ity.  Vibration sense was elicited using a 128 Hz turning 
fork at the hallux of  the big toe.  Pain perception was 
assessed by application of  pin prick on the proximal part 
of  the great toe to barely depress skin and results classi-
fied as present when patient could distinguish sharpness 
or absent when the patient was unable to distinguish it. 
The 3 perceptions were scored 0 if  present and normal, 
and 1 if  absent, reduced, or uncertain. Achilles deep ten-
don reflex was tested using standard patellar hammer and 
technique and graded as either 0 if  present (normal), 1 if  
present with reinforcement or 2 if  absent11.  Where there 
was previous foot amputation, the score awarded to the 
examined foot was doubled.  The NDS system is made 
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of  neuropathy score range from 0 - 10 which could also 
be used to assess severity of  peripheral neuropathy.  The 
severity of  neuropathy disability was graded as follows: 
mild (scores: 3–5), moderate (scores: 6–8), and severe 
(scores: 9–10)12. The NDS was validated and found to be 
65% sensitive and 91% specific for diagnosing diabetic 
neuropathy13 .  
Neuropathy Symptom Score (NSS):  All patients were 
asked whether they experienced pain or discomfort in 
their legs.  A description of  burning, numbness, or tin-
gling was assigned a score of  2, and fatigue, cramping, or 
aching was assigned a score of  1. If  the patient described 
the symptoms as occurring in their feet, calves, and else-
where, scores of  2, 1, and 0 were assigned, respectively. 
Nocturnal exacerbation of  symptoms was scored as exac-
erbation of  symptoms during the day as well as night was 
scored as 1, and exacerbation of  symptoms during the 
daytime alone was scored as 0. If  the symptoms had ever 
woken the patient from sleep, a score of  1 was assigned. 
The patients were asked if  any maneuver could reduce 
their symptoms; walking was assigned a score of  2, stand-
ing 1, and sitting or lying down 0.  Thus, the maximum 
symptom score was 9, and the severity of  symptoms was 
graded as follows: mild (scores: 3–4), moderate (scores: 
5–6), and severe (scores: 7–9)14,15. Gentile et al. found the 
symptoms to be 87% sensitive and 60% specific when 
compared to the gold standard nerve conduction studies 
(NCS) as reference16.
The diagnosis of  DPN depends on both subjective 
symptoms and signs of  neuropathy. We defined DPN as 
at least moderate signs (NDS ≥6)  according to Neurop-
athy Disability score with or without symptoms, or mild 
signs (NDS ≥3) with moderate symptoms ( NSS ≥5) us-
ing Neuropathy symptom score17,18.
Laboratory investigations: were performed on all study 
participants. These included a random serum lipid pro-
file, glycated hemoglobin levels and vitamin B 12 com-
plex levels.
Blood collection: under aseptic techniques, a vein pref-
erably in the antecubital fossa which was identified and 
between 6 mls of  whole blood was drawn.  It was then 
dispensed in to yellow top vacutainers for lipid profile 
(HDL, LDL, Total Cholesterol), red vacutainers for Vita-
min B 12 levels and purple top vacutainers for HBA1C. 
The blood in each tube was mixed gently and immediately 
delivered to the Mulago chemistry laboratory for anal-
ysis. For the serum lipid profile and vitamin B12 levels, 
the Cobas intergra machine was utilized. For HBA1C, 
high-performance liquid chromatography (HPLC) was 
used.
Statistical analysis
Statistical analysis was performed using STATA soft-
ware version 12 (Stata Corporation, College Station, TX, 
USA).  Continuous data have been expressed as mean 
± SD and categorical data as numbers and percentages. 
Variables associated with DPN were tested using bi-vari-
able analysis.  All factors with p<0.2 at bi-variable analysis 
were included in multivariable analysis using a multiple 
logistic regression.  Collinearity analysis found a signifi-
cant association between age and history of  hypertension 
(p<0.001).  Two models one including age and the other 
including history of  hypertension were then fitted and 
compared using AIC.  A model with age (excluding his-
tory of  hypertension) had the smallest AIC (260.36 com-
pared to 266.0) and was considered a better fit.  Goodness 
of  fit test of  this model was also done and was found to 
be fairly a good fit (p=0.065).  The results of  this model 
are shown under the adjusted results column. A P value 
<0.05 was considered significant.
Results
Baseline socio-demographic factors
A total of  two hundred forty-eight newly diagnosed di-
abetic patients were enrolled into this study.  The mean 
age (±SD) of  study participants was 48.5 (13.4) years.  Of  
all  the two hundred forty eight study participants, one 
hundred and fifty four were male, (62%) and 194 (78.2 
%) were above 40 years.  Fifty-six percent (140/248) were 
married while 76.2% (189/248) were residents from ur-
ban areas.  Fifty-four percent (134/248) had only primary 
level education. Fifty-seven percent (140/248) of  them 
were earning income below 200,000 shillings as shown 
in Table 1.
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Table 1: Social demographic characteristics of newly diagnosed diabetic  
patients attending Mulago Hospital 
 
  Frequency 
N = 248 
Percentage 
(%) 
Age categories in years 
  
    
<40 54 21.8 
40 – 49 75 30.2 
50 – 59 64 25.8 
≥60 55 22.2 
Gender     
Female 94 37.9 
Male 154 62.1 
Marital status     
Single 27 10.9 
Married 140 56.5 
Separated 49 19.8 
Widowed 32 12.9 
Residence     
Urban 189 76.2 
Rural 59 23.8 
Level of education     
None 34 13.7 
Primary 134 54.0 
Secondary 61 24.6 
Post-secondary 19 7.7 
Income level in Uganda shillings (Ugx)     
<200,000 140 56.5 
≥ 200,000 108 43.5 
  
Prevalence and severity of  peripheral neuropathy 
among newly diagnosed diabetic patients.
The prevalence of  peripheral neuropathy was 29.4 % 
(73/248) using the NDS and NSS criteria.  The mean 
age (±SD) in years among those with peripheral neurop-
athy and those without peripheral neuropathy was 54.1 
(12.6) and 46.8 (13.2) respectively. The mean age in years 
was different among these two groups with p-value of  
<0.001, (OR; 95% CI: 1.04 (1.02 – 1.07).   There were 
no significant differences in these two groups in the BMI 
kg/m2. 70.6% (175/248) had no peripheral neuropathy. 
Among study subjects with peripheral neuropathy, 53.4% 
(39/73) had moderate neuropathy with NDS score of  
6-8, 30.2% (22/73) had mild while 16.4% (12/73) had 
severe peripheral neuropathy with NDS scores of  9-10.  
Half  of  the newly diagnosed diabetic patients with severe 
clinical neuropathy (NDS >8) had painful neuropathic 
symptoms (i.e. NSS ≥5), while only 14.2% of  patients 
without clinical neuropathy (NDS ≤2) had painful symp-
toms using the neuropathy disability score.   Thirty-three 
percent of  newly diagnosed diabetics with severe neurop-
athy had no clinical symptom (NSS 0-2) (See figure 1).  
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Figure 1: Relationship between neuropathy symptoms and clinical severity of neuropathy 
Factors associated with peripheral neuropathy in 
newly diagnosed patients
The age 60 years and above  was associated with peripher-
al neuropathy, (OR 6.05, 95% CI, 2.08 – 17.63, p=0.001). 
Gender, level of  education and income level were not 
associated with peripheral neuropathy with p-values of  
0.254, 0.519 and 0.127 respectively (Table 2).








OR (95% CI) p value 
Age categories in years 
  
        
<40 5 (8.3) 49 (26.1) Reference   
40 – 49 14 (23.3) 61 (32.5) 2.25 (0.76 – 6.68) 0.144 
50 – 59 20 (33.3) 44 (23.4) 4.45 (1.54 – 12.87) 0.006* 
≥60 21 (35.0) 34 (18.1) 6.05 (2.08 – 17.63) 0.001* 
Gender         
Male 19 (31.7) 75 (39.9) Reference   
Female 41 (68.3) 113 (60.1) 1.43 (0.77 – 2.66) 0.254 
Marital status         
Married 33 (55.0) 107 (56.9) Reference   
Single 3 (5.0) 24 (12.8) 0.41 (0.11 – 1.43) 0.161 
No 29 (48.3) 129 (68.6) Reference   
Yes 31 (51.7) 59 (31.4) 2.34 (1.29 – 4.23) 0.005* 
Current alcohol 
consumption 
        
No 51 (85.0) 146 (77.7) Reference   
Yes 9 (15.0) 42 (22.3) 0.61 (0.28 – 1.35) 0.224 
1 Duration before diagnosing study patients with diabetes from the estimated start of 
diabetic symptoms like polyuria and polydipsia 
  
*statistically significant 
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Socio-demographic and clinical factors: Among study 
subjects the delay in initiating treatment of  more than 1 
year was associated with peripheral neuropathy, (OR 1.89; 
95% CI: 1.03 – 3.48), p=0.041). The history of  ever hav-
ing a foot ulcer and hypertension were significantly asso-
ciated with peripheral neuropathy with (OR 2.59; 95% 
CI: 1.03 – 6.49, p = 0.042) and (OR 2.34, 95% CI 1.29 
– 4.23, p= 0.005) respectively (Table 3).
Table 4 shows bivariate analysis of  laboratory results and 
diabetic peripheral neuropathy where 76.7% (P= 0.737) 
of  patients with neuropathy had abnormal HBA1C.  Vi-
tamin B12 was abnormal in only 1.7% (P=0.579) of  pa-
tients with peripheral neuropathy.  Normal lipid profile 
was generally protective against peripheral neuropathy. 
All the results were not statistically significant. 
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Table 3:Associations between clinical history factors and peripheral neuropathy. 
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Subsequent multivariate analysis showed that age groups, 
50-59 years (OR 3.72; 95% CI 1.25 – 11.03) p=0.018) 
and those aged ≥60 years (OR 6.62, 95% CI 2.22 – 19.70, 
p=0.001) were independently associated with peripheral 
neuropathy. The history of  ever having a foot ulcer was 
associated with peripheral neuropathy (OR 2.98; 95% CI: 
1.11 – 8.02, p=0.031) (Table 5). 
Table 4: Associations between laboratory results and peripheral neuropathy. 
Laboratory results Neuropathic N(%) None-neuropathic 
N (%)
















































0.95 (0.52 – 1.74)
Reference 
0.878
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Table 5: Unadjusted and adjusted effects for factors associated with peripheral 
neuropathy using a logistic regression. 
  Unadjusted OR 
(95% CI) 
P value Adjusted OR 
(95% CI) 
P value 
Age         
<40 Reference   Reference   
 
40 – 49 2.25 (0.76 – 6.68) 0.144 2.07 (0.68 – 6.28) 0.197 
50 – 59 4.45 (1.54 – 12.87) 0.006 3.72 (1.25 – 
11.03) 
0.018 
≥60 6.05 (2.08 – 17.63) 0.001 6.62 (2.22 – 
19.70)  
 Duration before diagnosed 
with diabetes 
        
<1 year (no delay) Reference   Reference   
≥ 1 year (delay) 1.89 (1.03 – 3.48) 0.041 1.79 (0.94 – 3.44) 0.077 
Missed diagnosis         
No Reference   Reference   
Yes 2.59 (1.03 – 6.49) 0.042 2.85 (1.05 – 7.75) 0.040 
Ever had foot ulcer         
No Reference   Reference   
Yes 2.59 (1.03 – 6.49) 0.042 2.98 (1.11 – 8.02) 0.031 
 
Discussion
Peripheral neuropathy remains a challenge among diabet-
ic patients and early institution of  hypoglycemic agents 
may slow its progression. Increasing age, longer duration 
of  diabetes and poor glycemic control are well recognized 
risk factors for peripheral neuropathy while cigarette 
smoking, retinopathy, hypertension, obesity, hyperlipid-
emia and micro-albuminuria have also been implicated as 
potential risk markers19.
 
Prevalence of  diabetic peripheral neuropathy
The overall prevalence of  DPN among newly diagnosed 
diabetic patients was 29.4 %. This is the first study to 
assess the severity and factors associated with peripheral 
neuropathy in Uganda among newly diagnosed diabet-
ics, earlier studies have described peripheral neuropathy 
among patients’ attending the out-patient clinics and 
receiving hypoglycemic agents. This prevalence is lower 
than a prevalence of  46.4% reported from a chart re-
view of  newly diagnosed diabetics reported in Uganda20. 
However, this study among newly diagnosed diabetics 
was based on symptoms and no assessment of  severity 
was performed. It is also important to note that a third 
of  the study participants with clinically severe neuropath-
ic signs had no clinical symptoms This study had similar 
findings to other studies in India, Egypt,  with a prev-
alence of  29% using the same diagnostic criteria21,22. In 
various Western populations, the prevalence of  DPN in 
newly diagnosed diabetic patients varies widely from 10% 
to 48%23-25.  In other studies, from sub –Saharan Afri-
ca, Osuntokun in Nigeria reported higher levels of  48% 
while the frequency of  peripheral neuropathy has been 
reported to vary from 9.5-36.4% among diabetic patients. 
These conflicting figures may be due to the differences in 
the methodologies and techniques of  diagnosing periph-
eral neuropathy26,27.
This may be due to different methodologies employed for 
detection of  neuropathy such as the use of  nerve conduc-
tion studies as well as variability in patient ages and time 
elapsed before diagnosis.  However, racial differences in 
DPN may also be relevant within these populations28. 
This high prevalence of  DPN among newly diagnosed 
diabetics indicates that our patients may be presenting 
late to clinics for attendant care. This may be attributed 
to low knowledge, attitudes or mis-diagnosis/delayed di-
agnosis in Uganda. Lack of  regular medical care and poor 
health seeking behavior may play an important role.
Severity of  diabetic peripheral neuropathy
Most of  the patients had moderate to severe neuropathy 
with high neuropathic symptom scores.  Approximate-
ly half  of  our patients with clinically severe neuropathy 
had no or mild symptoms which was consistent with a 
study in United Kingdom in 48% of  patients29.  Further-
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more, approximately 15% of  our patients without clinical 
neuropathy on examination had significant painful neu-
ropathic symptoms (NSS≥5), indicating the large dispar-
ity between signs and symptoms.  Diabetic patients with 
impaired glucose tolerance and no apparent neuropathy 
develop painful neuropathic symptoms and small nerve 
fiber damage30.  This poses a challenge in assessing for 
this condition if  50% of  the patients have no symptoms 
and hence requires a good clinical examination on all di-
abetic patients irrespective of  symptoms of  neuropathy. 
This emphasizes the need not only to inquire about these 
symptoms but also to perform a neurological examina-
tion to make an early diagnosis.
Factors associated with Diabetic peripheral neurop-
athy
Previous studies have identified several risk factors for 
DPN such as age, poor glycemic control, the duration 
of  diabetes, gender, height, body mass index, retinopathy, 
hypertension, smoking, alcohol consumption and foot ul-
cers23,24,31.  In the current study, age at diagnosis and histo-
ry of  foot ulcers were independent risk factors for DPN. 
For each decade increase in age, the prevalence of  DPN 
increased significantly and the mean age (SD) for DPN 
was 54.1 (12.6).  This mean age is similar to that in other 
studies from Nigeria (54.8 ± 12.1)32, Bangladesh (54.8 ± 
12.1)33, India (51.3 ±12.3)34 and Iran(57.0±10.6)35.  How-
ever it was higher in China (69.6±9.5)36 and Sir Lanka 
(62.1 ± 10.8)37 because their study population was above 
50 years which was relatively older than ours.
Limitations
The study had various limitations, the diagnosis of  pe-
ripheral neuropathy is improved by nerve conduction 
testing unfortunately this test is not available here which 
could have led to under diagnosis. This was a referral 
hospital setting so the results may not be generalized to 
the whole of  Uganda. Triglycerides were not considered 
since patient did not fast which could underestimate the 
role of  lipids as associated factors for peripheral neurop-
athy.  This was because it was inconvenient to keep the 




29.4% of  recently diagnosed patients with diabetes had 
DPN. DPN was associated with an age of  60 years and 
above as well as history of  foot ulcers. There is an urgent 
need to routinely screen for diabetes among the elder-
ly population and examine newly diagnosed diabetic pa-
tients irrespective of  their clinical symptoms. Screening 
for DPN may be a cost-effective means to prevent dia-
betic foot ulcers in Ugandan patients.
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